Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337616 | 0.80 | MAP4K4 (0.58) | PDPK1NTRK1AXL | |
| SCHEMBL12269997 | 0.80 | CCNT1 (0.55) | CCNT1CCND1CCNCCDK8CDK7 | |
| SCHEMBL956760 | 0.79 | GSK3B (0.45) | SYKGSK3BCCR6 | |
| SCHEMBL29476743 | 0.78 | MKNK1 (0.68) | CCNT1CCND1CCNCCDK8CDK7 | |
| SCHEMBL3663216 | 0.78 | CCNT1 (0.56) | CCNT1CCND1CCNCCDK8CDK7 | |
| SCHEMBL4516742 | 0.78 | DHODH (0.59) | FLT1CDK2CSF1RFLT3KDR | |
| SCHEMBL18296109 | 0.77 | NNMT (0.53) | HPGDS | |
| SCHEMBL3662920 | 0.76 | MKNK1 (0.71) | CCNT1CCND1CCNCCDK8CDK7 | |
| SCHEMBL3664142 | 0.76 | FYN (0.57) | CCNT1CCND1CCNCCDK8CDK7 | |
| SCHEMBL3636687 | 0.75 | CCNT1 (0.53) | CCNT1CCND1CCNCCDK8CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9586932-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8598360-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CCNT1 1122/4885CCND1 1240/4885CCNC 1522/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CCNT1 1122/4885CCND1 1240/4885CCNC 1522/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | CCNT1 1100/4885CCND1 1191/4885CCNC 1494/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CCNT1 1122/4885CCND1 1240/4885CCNC 1522/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | CCNT1 1040/4885CCND1 1163/4885CCNC 1559/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CCNT1 1122/4885CCND1 1240/4885CCNC 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.